Prelude Capital Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Prelude Capital Management’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-1,500	Closed	-$16K	–	1875
2015 Q2	$16K	Buy	+1,500	New	+$19.3K	﹤0.01%	1492

Other funds holding INFI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Prelude Capital Management's INFI Position: Q4 2018 in Review

Prelude Capital Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2018, closing a stake of 157,247 shares — an estimated $426K sold.

Prelude Capital Management first reported a position in INFI in Q2 2013 and held it in 15 quarters. The position peaked at $426K in Q3 2018. 64 funds tracked by Wall St. Rank hold INFI as of Q4 2018.

Prelude Capital Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
Prelude Capital Management sold 157,247 Infinity Pharmaceuticals, Inc. shares in Q4 2018, an estimated $426K.
Prelude Capital Management first reported a position in Infinity Pharmaceuticals, Inc. in Q2 2013 and held it in 15 quarters.
Prelude Capital Management's Infinity Pharmaceuticals, Inc. position peaked at $426K in Q3 2018.
64 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2018.

Based on Prelude Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.